Klingman & Associates 13F: New $502K Stake in BSX
Key Points
- Klingman & Associates purchased a new stake in Boston Scientific Corporation (NYSE:BSX) consisting of 11,492 shares, as revealed in its Form 13F filing on October 20, 2026.
- Boston Scientific Corporation recently traded around $45.59, sitting near the lower end of its 52-week range.
- Several major institutional investors adjusted their positions in the medical device maker during recent quarters.
Get Boston Scientific text alerts
We text you when insiders, Congress, analysts or big funds move on $BSX.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Boston Scientific Corporation alert may contain errors. Disclosures
Klingman & Associates opened a new position in Boston Scientific Corporation (NYSE:BSX) by purchasing 11,492 shares, according to a Form 13F filing filed with the SEC on October 20, 2026. The newly initiated stake was valued at approximately $501,626 based on filing data.
BSX
Boston Scientific Corporation
What Changed in Klingman & Associates's Boston Scientific Corporation Position
The fund took a brand-new position in the healthcare company, acquiring 11,492 shares. The holding had a reported value of $501,626 at the time of the filing.
Other Institutional Activity in Boston Scientific Corporation
Other large investors also adjusted their holdings in the medical device maker recently. Banque Pictet & Cie reduced its holdings by 694,882 shares, ending with 373,583 shares worth about $16,306,898. Y-Intercept cut its stake by 993,646 shares to hold 126,685 shares valued at about $5,529,800. Primecap Management Company grew its holdings by 17,991,834 shares, ending with 50,520,914 shares worth about $2,302,743,352. Shaw D.E. & Co., Inc. grew its holdings by 1,145,109 shares, ending with 25,457,409 shares worth about $1,160,348,748. Massachusetts Financial Services Co. grew its holdings by 13,862,468 shares, ending with 24,859,191 shares worth about $1,133,081,971.
Boston Scientific Corporation Stock Up 2.7%
Boston Scientific Corporation shares recently traded around $45.59 as of October 21, 2026, close to the $45.58 close price recorded on the filing date of October 20, 2026. The stock trades below its 50-day and 200-day moving averages, and sits well below its 52-week high of $105.65 while resting above its 52-week low of $41.39.
Recent Earnings
Boston Scientific Corporation reported its latest financial figures ahead of an upcoming earnings report scheduled for October 28, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
12 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 0.7%. Revenue met estimates.
-
Profit surprise
EBITDA met by 0 percent. Operating income missed by 13 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 12 target cuts.
-
Earnings quality
Gross margin up 6.2 points. Operating margin up 1.4 points. Positive free cash flow.
Earnings Call Summary
Boston Scientific reported first quarter sales of $5.2 billion, up 9.4 percent, and beat on earnings at $0.80 per share. However, management revealed major headwinds in three key franchises. The EP cardiology ablation business, which grew 22 percent this quarter, is now expected to slow to 10 percent full year as competition from Medtronic, J and J, and Abbott pressures U.S. share. WATCHMAN, which grew 19 percent, slowed sharply in February as stand-alone procedures fell even as concomitant adoption grew. Urology nearly flatlined at 1 percent growth due to problems in stone management and sacral neuromodulation. Management said the company lost more market share than expected and hospital capacity constraints are limiting WATCHMAN procedure volume.
Guidance The company cut its full year sales growth guidance from an expected 8 to 10 percent range down to 6.5 to 8 percent. They expect second quarter sales to grow only 5 to 7 percent year over year. The company now guides full year earnings per share to $3.34 to $3.41, still up 9 to 11 percent but well below prior expectations.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Insider Buying and Selling at Boston Scientific Corporation
Company insiders were active in the market prior to the filing. Chief Executive Officer Michael F. Mahoney bought 186,240 shares on August 3, 2026, at an average price of $48.33 for a total value of $9,001,408. Director David C. Habiger bought 1,182 shares on August 4, 2026, valued at $56,887, and later bought 2,100 shares on August 5, 2026, at a price of $47.59 for a total of $99,937. Director Susan E. Morano bought 2,040 shares on August 25, 2026, at a price of $49.22 for a total value of $100,408.
Analysts Set New Price Targets
Wall Street firms updated their views on the stock ahead of the filing. On September 21, 2026, Oppenheimer maintained an Outperform rating while lowering its price target to $65.00 from $85.00. Wells Fargo maintained an Equal-Weight rating on September 24, 2026, cutting its target from $50.00 to $48.00. Citigroup maintained a Neutral rating on October 5, 2026, dropping its target to $48.00 from $50.00. Barclays initiated coverage on October 7, 2026, with an Equal-Weight rating and a $48.00 price target. Truist Securities maintained a Buy rating on October 14, 2026, lowering its target to $51.00 from $57.00. The consensus rating stands at buy with a mean price target of $59.24 across 29 analyst opinions.
About Boston Scientific Corporation
Boston Scientific Corporation designs and manufactures medical devices utilized across various interventional medical specialties globally. The company operates through two primary divisions, MedSurg and Cardiovascular, providing equipment used by healthcare professionals worldwide.
Bottom Line
Investors will watch for the company's next earnings report on October 28, 2026, to gauge ongoing financial performance and operational trends.
Related Filing Alerts
Source: Klingman & Associates's 13F filing on $BSX (Oct 20, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts